Abstract
Objectives:This study examined the effect of metformin use on the prognosis of gastric cancer patients.Materials and Methods:The study population comprised 2187 patients who underwent curative gastrectomy for the treatment of gastric cancer. They were divided into 3 groups: metformin (n=103), non-metformin (n=139), and non-diabetes mellitus (DM) (n=1945) according to their history of type 2 DM and metformin use. Survival, disease recurrence, and the pathologic stage were analyzed.Results:Overall survival was better in the metformin group than in the non-DM group (P=0.005). Metformin use was an independent prognostic factor of overall survival, cancer recurrence, and peritoneal recurrence. An effect of metformin use was especially notable in patients with T4 or N0 disease.Conclusions:Metformin improves the survival of patients with gastric cancer and type 2 DM.
| Original language | English |
|---|---|
| Pages (from-to) | 909-917 |
| Number of pages | 9 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 42 |
| Issue number | 12 |
| DOIs | |
| State | Published - 1 Dec 2019 |
Bibliographical note
Publisher Copyright:© 2019 Wolters Kluwer Health, Inc. All rights reserved.
Keywords
- diabetes mellitus
- metformin
- prognosis
- stomach neoplasms
- survival
